Trademark name: Lapatinib

English name: Tykerb, lapatinib

Specification: .25g (7 tablets/box, 56 tablets/box)

Yiteng Pharmaceutical, a professional pharmaceutical company, announced on April 9, 213 that it has obtained a new drug Telisha for advanced or metastatic breast cancer from GlaxoSmithKline. Ni Xin, Chairman and CEO of Yiteng Pharmaceutical, said that this is the first time that China Pharmaceutical Company has participated in the listing of global patented anti-tumor drugs in China.

Tylisa from GlaxoSmithKline? (English name: Tykerb? , generic name: lapatinib mesylate tablets (trade name: lapatinib) is an innovative drug for the treatment of tumors, which has been listed in more than 1 countries and regions, and was recently approved by China china food and drug administration (SFDA) for the treatment of advanced or metastatic breast cancer.

according to the cooperation agreement between Yiteng Pharmaceutical and GlaxoSmithKline, Yiteng Pharmaceutical exclusively obtained Telisha? The right to import, market, promote, distribute and sell in Chinese mainland.